Product Information
GENVOYA TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $143.3532 per EA under NDC 61958190101. Its NADAC has been published 555 times since Feb 17, 2016.
FDA first approved this application on Nov 5, 2015.
Strength
150; 150; 200; 10 mg/1; mg/1; mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958190101
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA207561FDA Approved
11/5/2015
On Market Since
11/5/2015
Pharmacological Classes
Price Statistics
The NADAC for GENVOYA TABLET has been published 555 times since Feb 17, 2016, and over the history we have for it it has risen 71.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $143.3532 per EA |
|---|---|
| All-time high | $143.3532 (Sep 30, 2026) |
| All-time low | $82.7351 (Jan 18, 2017) |
| 52-week high | $143.3532 |
| 52-week low | $136.6495 |
| Median price | $109.9641 |
| Average price | $111.1094 |
| Largest weekly change | +6.9% (Feb 15, 2017) |
| Weeks tracked | 555 |
| Tracking since | Feb 17, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytochrome P450 3A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GENVOYA TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GENVOYA TABLET, manufactured by Gilead Sciences, Inc., is $143.3532 per EA (NDC 61958190101), effective Sep 30, 2026.
How has the price of GENVOYA TABLET changed over time?
Over the history we have for it, the NADAC for GENVOYA TABLET has risen 71.5%. It has been tracked across 555 weekly CMS publications since Feb 17, 2016.
What are the highest and lowest recorded NADAC prices for GENVOYA TABLET?
Since Feb 17, 2016, the NADAC for GENVOYA TABLET has ranged from a low of $82.7351 (Jan 18, 2017) to a high of $143.3532 (Sep 30, 2026), with a median of $109.9641 per EA.
Are there cheaper alternatives to GENVOYA TABLET?
No other NADAC-published product currently shares the active ingredient and strength of GENVOYA TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GENVOYA TABLET?
GENVOYA TABLET (NDC 61958190101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.